Dimensional Fund Advisors LP Sells 838,228 Shares of Perrigo Company plc $PRGO

Dimensional Fund Advisors LP lessened its stake in Perrigo Company plc (NYSE:PRGO) by 11.3% in the 1st quarter, Holdings Channel reports. The institutional investor owned 6,567,616 shares of the company’s stock after selling 838,228 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Perrigo were worth $70,525,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. EverSource Wealth Advisors LLC lifted its position in Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after acquiring an additional 1,014 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Perrigo by 161.5% in the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after purchasing an additional 1,213 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Perrigo in the 4th quarter valued at about $28,000. Finally, CWM LLC lifted its holdings in shares of Perrigo by 230.0% in the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after purchasing an additional 1,527 shares in the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PRGO. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $19.33.

Perrigo Price Performance

Shares of NYSE PRGO opened at $10.09 on Friday. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -0.77, a PEG ratio of 1.22 and a beta of 0.51. The business has a 50-day moving average of $10.53 and a 200-day moving average of $11.64. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. Perrigo Company plc has a fifty-two week low of $9.23 and a fifty-two week high of $27.33.

Perrigo (NYSE:PRGO) last released its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The business had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the prior year, the company posted $0.60 earnings per share. Perrigo’s revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, sell-side analysts predict that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th will be paid a dividend of $0.29 per share. The ex-dividend date is Friday, August 28th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 11.5%. Perrigo’s dividend payout ratio is currently -8.85%.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.